Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE006 (GBR) (Dr. Rossi)
· consented 2022-05-18
Adverse events
4
Serious AEs
2
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 68); relationship: N
severe
serious
assessed
2026-08-18
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-26 (study day 94); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-10 (study day 109); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-10 (study day 109); relationship: N; serious criteria: life-threatening
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.